Dendreon Corp., of Seattle, made four abstract presentations on Provenge (sipuleucel-T) and one abstract for DN24-02, an investigational active cellular immunotherapy, from ongoing clinical trials at the 2014 Genitourinary Cancers Symposium (ASCO GU).